LQDA (Liquidia) Future Price to Earnings

Official company branding of Liquidia (LQDA)

The prospects for Liquidia Corporation (LQDA) rely on the commercial success of Yutreqsa and the outcome of patent litigation. The company's 12-month forward P/E clearly demonstrates capital dynamics, with the metric standing at 14.70. Business development is based on a strategic partnership in drug delivery, while its image as a bold innovator attracts investors who believe in the disruptive potential of the brand's technologies.

liquidia.com - LQDA Market Cap to Future Earnings Ratio (period 07/04/2022 - 11/16/2026)

Summary analytical data breakdowns for liquidia.com (LQDA)

- current price and projected stock value:
- business market valuation indicators:
Fundamental valuation:LQDA Liquidia Technologies
Brand item of Liquidia Corporation

Forward P/E measures market expectations for capitalization payback via projected net income, where extreme values signal either overbought conditions or a critical collapse in earnings. When analyzing the forward price-to-earnings ratio of Liquidia Corporation (LQDA), investors must consider that high R&D expenses and the absence of stable revenue temporarily inflate this coefficient until the full commercial launch of the drugs.

Competing companies

Future Price to Earnings haleon.com (HLN)|KVUE (Kenvue Health) - Future Price to Earnings Multiple|Future Price to Earnings Verona Pharma PLC VRNA|Jyong Biotech (MENS) - Projected Price to Earnings Ratio|LGND: Projected Price to Earnings|Amneal - Market Cap to Future Earnings Ratio|PRGO: Forward P/E Multiple|Alvotech Corp - Future Price to Earnings Multiple|GLPG (Galapagos N.V.) - Forward P/E Multiple|Projected Price to Earnings Ratio anipharmaceuticals.com ANIP|Future Price to Earnings MannKind (MNKD)|AMPH (Amphastar Pharmaceuticals, Inc.) - Future Price to Earnings Multiple|Future Price to Earnings Pacira BioSciences, Inc. PCRX|Forward P/E Multiple ARS Corp SPRY|Theravance Biopharma - Forward P/E Multiple|Forward Price to Earnings Multiple Aquestive Therapeutics, Inc. (AQST)|scPharmaceuticals (SCPH) - Future Price to Earnings|Projected Price to Earnings Tectonic Therapeutic, Inc.|TNXP (Tonix Pharmaceuticals Holding) - Forward P/E Multiple|Price to Future Earnings Ratio SXTC (China SXT Pharmaceuticals)|Forward P/E Multiple EPRX|Forward P/E Multiple bioharvest.com (BHST)|Future Price to Earnings Invizyne Technologies EXOZ|ORMP: Price to Future Earnings Ratio|ENTX: Projected Price to Earnings|HYFT: Future Price to Earnings|ABVC BioPharma Inc. (ABVC) - Future Price to Earnings|cumberlandpharma.com (CPIX) - Forward P/E Multiple|QNTM (Quantum BioPharma) - Forward P/E Multiple|FGEN: Future Price to Earnings Multiple|Forward P/E Multiple TELO|Forward P/E Multiple Rani Therapeutics Holdings (RANI)|Forward P/E Multiple SNYR (Synergy CHC Corp)|Rallybio Corporation (RLYB) - Projected Price to Earnings Ratio|LEXX - Future Price to Earnings|PULM (Pulmatrix) - Price to Future Earnings Ratio|Pheton Holdings Ltd (PTHL) - Future Price to Earnings|Aptorum - Future Price to Earnings Multiple|Projected Price to Earnings LYRA|Projected Price to Earnings Impact BioMedical Inc (IBO)|Forward P/E Multiple TNFA|YCBD: Price to Expected Earnings Ratio|Future Price to Earnings PainReform PRFX|altamiratherapeutics.com (CYTO) - Projected Price to Earnings Ratio|LIPO: Projected Price to Earnings|OPTN (optinose.com) - Price to Future Earnings Ratio|PIRS: Forward P/E Multiple|PROC - Market Cap to Projected Earnings|PTPI (Petros Pharma) - Forward P/E Multiple|Future Price to Earnings QLI|Forward P/E Multiple SLRN|Market Cap to Future Earnings Ratio TFFP